Immunogenicity of biological agents in inflammatory bowel disease

被引：9
作者：
Fefferman, DS [1 ]
Farrell, RJ [1 ]
机构：
[1] Harvard Univ, Sch Med, Div Gastroenterol, Ctr Inflammatory Bowel Dis, Boston, MA 02215 USA
来源：
INFLAMMATORY BOWEL DISEASES | 2005年 / 11卷 / 05期
关键词：
D O I：
10.1097/01.MIB.0000161536.97412.41
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：497 / 503
页数：7
相关论文
共 34 条
[1]  
*ABB LAB, 2004, AD PACK INS
[2]   Development of autoantibodies before the clinical onset of systemic lupus erythematosus [J].
Arbuckle, MR ;
McClain, MT ;
Rubertone, MV ;
Scofield, RH ;
Dennis, GJ ;
James, JA ;
Harley, JB .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (16) :1526-1533
[3]   Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease [J].
Baert, F ;
Noman, M ;
Vermeire, S ;
Van Assche, G ;
D'Haens, G ;
Carbonez, A ;
Rutgeerts, P .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (07) :601-608
[4]  
*CENT INC, 2004, REM PACK INS
[5]   The incidence and management of infusion reactions to infliximab: A large center experience [J].
Cheifetz, A ;
Smedley, M ;
Martin, S ;
Reiter, M ;
Leone, G ;
Mayer, L ;
Plevy, S .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2003, 98 (06) :1315-1324
[6]   Infliximab for refractory ulcerative colitis [J].
Chey, WY ;
Hussain, A ;
Ryan, C ;
Potter, GD ;
Shah, A .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2001, 96 (08) :2373-2381
[7]   The safety profile of infliximab in patients with Crohn's disease: The Mayo Clinic experience in 500 patients [J].
Colombel, JF ;
Loftus, EV ;
Tremaine, WJ ;
Egan, LJ ;
Harmsen, WS ;
Schleck, CD ;
Zinsmeister, AR ;
Sandborn, WJ .
GASTROENTEROLOGY, 2004, 126 (01) :19-31
[8]   Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis [J].
Creed, TJ ;
Norman, MR ;
Probert, CSJ ;
Harvey, RF ;
Shaw, IS ;
Smithson, J ;
Anderson, J ;
Moorghen, M ;
Gupta, J ;
Shepherd, NA ;
Dayan, CM ;
Hearing, SD .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 18 (01) :65-75
[9]   Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: A randomized controlled trial [J].
Farrell, RJ ;
Alsahli, M ;
Jeen, YT ;
Falchuk, KR ;
Peppercorn, MA ;
Michetti, P .
GASTROENTEROLOGY, 2003, 124 (04) :917-924
[10]  
Feagan B, 2003, GASTROENTEROLOGY, V125, P606
1234